08:13 AM EST, 11/06/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) reported Q3 non-GAAP net income Wednesday of $0.10 per diluted share, compared with a loss of $0.01 a year earlier.

Analysts polled by Capital IQ expected $0.05 per share.

Net products sales for the quarter ended Sept. 30 were $141.5 million, up from $103.5 million a year earlier.

Analysts surveyed by Capital IQ expected $135 million.

The company said it now expects 2024 revenue to grow 30% to 32% compared with its prior growth guidance range of 26% to 31%.

Amicus shares were up 4.2% in premarket activity on Wednesday.